Table 1. Design of Randomized Clinical Trials of Systemic Therapy in Breast Cancer, Colorectal Cancer, and Non–Small Cell Lung Cancer (NSCLC) Published in 7 Major Journals, 1995-2020.
| Characteristic | No. (%) | ||
|---|---|---|---|
| 1995-20041 (n = 167) | 2005-20092 (n = 137) | 2010-2020 (n = 298) | |
| Disease site | |||
| Breast | 81 (49) | 69 (50) | 132 (44) |
| NSCLC | 39 (23) | 36 (26) | 111 (37) |
| Colorectal | 47 (28) | 32 (23) | 55 (19) |
| Setting | |||
| Palliative | 101 (60) | 77 (56) | 206 (69) |
| Adjuvant | 61 (37) | 52 (38) | 73 (25) |
| Neoadjuvant | 5 (3) | 8 (6) | 19 (6) |
| Study designa | |||
| Median sample size | 446 (167) | 722 (137) | 682 (298) |
| Median follow-up, mo | 47 (105) | 37 (104) | 25 (261) |
| Study treatmentsb | |||
| Any chemotherapy | 124 (74) | 115 (84) | 202 (68) |
| Any hormonal agent | 18 (11) | 23 (17) | 30 (10) |
| Any targeted/immune agentc | 7 (4) | 40 (29) | 218 (73) |
| Primary end pointd | |||
| OS | 82 (49) | 50 (36) | 86 (29) |
| DFS/RFS/EFS | 24 (14) | 38 (28) | 58 (19) |
| PFS | 0 | 25 (18) | 125 (42) |
| Other | 55 (32) | 24 (18) | 29 (10) |
| Industry funding | 95 (57) | 107 (78) | 265 (89) |
Abbreviations: DFS, disease-free survival; EFS, event-free survival; OS, overall survival; PFS, progression-free survival; RFS, relapse-free survival.
a
Number of studies for which these data are available is shown in parentheses.
b
Reflects treatments in either experimental or control groups.
c
Nonhormonal targeted agent.
d
Data shown are for studies in which a primary end point was either explicitly identified or implied in the article.